RSV F antigen vaccine - Clover Biopharmaceuticals

Drug Profile

RSV F antigen vaccine - Clover Biopharmaceuticals

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clover Biopharmaceuticals
  • Class Respiratory syncytial virus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 28 Dec 2017 Clover Biopharmaceuticals in-licenses Trimer-Tag© technology from GenHunter Corporation worldwide (Clover Biopharmaceuticals website, December 2017)
  • 28 Dec 2017 RSV F antigen vaccine - Clover Biopharmaceuticals is available for licensing as of 28 Dec 2017.
  • 28 Dec 2017 GenHunter Corporation has patent protection for Trimer-Tag© technology in USA, Europe, Japan and China (GenHunter Corporation website, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top